

Policy and Procedures for Infection Control in Pharmacy Services; New initiative Project in Saudi Arabia

Yousef Ahmed Alomi*,  BSc. Pharm, MSc. Clin Pharm, BCPS, BCNSP, DiBA, CDE Critical Care Clinical Pharmacists TPN Clinical Pharmacist, Freelancer Business Planner, Content Editor, and Data Analyst, Riyadh, SAUDI ARABIA.
Anhar Alyousef, Pharm D
Innova Healthcare Company, Riyadh, SAUDI ARABIA.

Correspondence:

Dr. Yousef Ahmed Alomi, BSc. Pharm, MSc. Clin Pharm, BCPS, BCNSP, DiBA, CDE Critical Care Clinical Pharmacists TPN Clinical Pharmacist, Freelancer Business Planner, Content Editor, and Data Analyst, P.O.BOX 100, Riyadh 11392, Riyadh, SAUDI ARABIA.

Phone no: +96504417712

E-mail: yalomi@gmail.com

Received: 08-10-2021;

Approved: 12-12-2021.

Copyright: © the author(s), publisher and licensee Pharmacology, Toxicology and Biomedical Reports. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License

Access this article online



www.ptbreports.org

DOI:
10.5530/PTB.2022.8.6

Various pharmacy practice and pharmacy administration programs were offered by pharmacy leaders in previous years.¹⁻³ Besides, pharmacy services have been expanded in recent years through a new model of the new Saudi Vision 2030.³⁻¹¹ Pharmacy infection control was one of the critical programs.¹²⁻¹³ Infection control services are one of the most important healthcare programs.¹⁴⁻¹⁸ It prevents the spread and transmission of infection to patients and healthcare-related products and procedures. It protects patients from infection-related problems.¹⁴⁻¹⁸ Various infection-related issues have arisen in pharmacy practice.¹⁹⁻³⁰ That has happened with pharmaceutical products. That happened while the parenteral medications were being prepared. The infectious products infiltrated the patients, infecting them and causing morbidity and mortality.¹⁹⁻³⁰ That has occurred due to infection-related injury is not a healthy practice in pharmacy. Thus, numerous international pharmacy guidelines emphasize infection prevention and control during medication preparation through the use of infection control tools.³¹⁻³³ Personal protective equipment and hand hygiene were also included. Apart from that, pharmacy practice requires the use of hand sanitizers and disinfectants.³¹⁻³³ Additionally, pharmacy waste is a source of infection, as are their procedures for dealing with it.³¹⁻³³ Utilizing these tools in specific locations throughout pharmacy departments was insufficient to address all possible causes of infection-related problems. It requires a pharmacy environment and workplace, vaccination and occupational safety of pharmacy staff, and infection control surveillance in pharmacy services. Apart from that, antibiotic prescription Pharmacoepidemiology and antibiotic resistance in bacteria.¹⁴⁻¹⁸ These are a series of articles about the new infection control initiative in pharmacy practice, which encompasses all previous issues on infection prevention and control, infection prevention and control of pharmacist competency, and pharmacy infection control quality management. These articles were written as policies and procedures to facilitate pharmacists' implementation of pharmaceutical care services.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

Consent for Publications

Informed consent was obtained from all the participants

Ethical Approval

This research is exempted from research and ethical committee or an institutional review board (IRB) approval.

<https://www.hhs.gov/ohrp/regulations-and-policy/decision-charts-2018/index.html>

ORCID ID

Yousef Ahmed Alomi  <https://orcid.org/0000-0003-1381-628X>

REFERENCES

1. Ahmed Y. Pharm A, Pharm C. Natl Pharm Pract Programs Minist Health Saudi Arabia. 2015;1(2):17-8.
2. Alomi YA. National pharmacy administration programs at Ministry of Health in Saudi Arabia. BAOJPS. 2015;1(2):1-2. doi: 10.24947/2380-5552/1/2/109.
3. Alomi YA, Alghamdi SJ, Alattyh RA, Elshenawy RA. The evaluation of pharmacy strategic plan in past. Commun Med. 2013-2016 and Forecasting of New Vision 2030 at Ministry of Health in Saudi Arabia. J Pharm Pract;2018(Jun 10);4(2):93-101.
4. Ahmed Alomi Y, Jamaan Alghamdi S, Abdullah Alattyh R, Shorog E, Alshahran A, Alasmay S, *et al.* National survey of pharmacy practice at MOH hospitals in Saudi Arabia 2016-2017: pharmacy management and resource. J Pharm Pract. Commun Med. 2018;4(1s):s1-16.
5. Alomi YA, Alghamdi SJ, Alattyh RA, Shorog E, Alshahran A, Alasmay S, *et al.* National survey of pharmacy practice at Ministry of Health Hospitals in Saudi Arabia 2016-2017: prescribing and medication management. J Pharm Pr Community. Med. 2018;5:S54-9.
6. Alomi YA, Jamaan Alghamdi S, Abdullah Alattyh R, Shorog E, Alshahran A, Alasmay S, *et al.* National survey of pharmacy practice at MOH hospitals in Saudi Arabia 2016-2017: preparation of medications and dispensing. J Pharm Pract. Commun Med. 2018;4(1s):s54-9.
7. Alomi YA, Shorog E, Alshahrani A, Alasmay S, Alenazi H, Almutairi A, *et al.* National survey of pharmacy practice at MOH hospitals in Saudi Arabia 2016-2017: drug monitoring and patients education. J Pharm Pract. Commun Med. 2018;4(1s):s17-22.
8. Alomi YA, Alghamdi SJ, Alattyh RA. National survey of pharmacy practice at MOH hospitals in Saudi Arabia. Med 2018. 2016-2017 : Clinical Pharmacy Services. J Pharm Pr Community;4(1):1S-8S.
9. Ahmed Alomi Y, Jamaan Alghamdi S, Abdullah Alattyh R, Shorog E, Alshahran A, Alasmay S, *et al.* National survey of pharmacy practice at MOH hospitals in Saudi Arabia 2016-2017: pharmacy quality management and drug information service. J Pharm Pract. Commun Med. 2018;4(1s):s34-9.
10. Alomi YA, Alghamdi SJ, Alattyh RA. National survey of pharmacy practice at MOH hospitals in Saudi Arabia 2016-2017: pharmacy computerized and technology. J Pharm Pract. Commun Med. 2018;4(1s):s40-6.
11. Alomi YA. New pharmacy model for vision 2030 in Saudi Arabia. J Pharm Pract. Commun Med.

- 2017;3(3).
12. Alomi YA, Alyousef AM. Infection control pharmacist: A new initiative project in the Kingdom of Saudi Arabia. *PTB Reports*. 2021;7(2):40-3. doi: 10.5530/PTB.2021.7.8.
 13. Alomi YA, Abdullah Hakami LE, Yahya Khayat NA, Bamagaus YA, Rafuden Bakhsh TM, Adnan Khayat N, *et al*. Mass gathering (hajj) pharmacy infection control: new initiative in Saudi Arabia. *IJPCS*. 2020;9(1):5-9. doi: 10.5530/ijpcs.2020.9.2.
 14. US Department of Health and Human Services, Centers for Disease Control and Prevention. Infection control in healthcare personnel: infrastructure and routine practices for occupational infection prevention and control services recommendations only. p. 1-8; 2019. Available from: <https://www.cdc.gov/infectioncontrol/pdf/guidelines/infection-control-HCP-recommendations-only-H.pdf> [cited 23/3/2022].
 15. WHO. INFECTION Prevention AND CONTROL ASSESSMENT FRAMEWORK AT THE FACILITY LEVEL Introduction and user instructions [internet]. Vol. 2016; 2018. Available from: <http://www.who.int/infection-prevention/publications/core-com-> [cited 23/3/2022].
 16. Ontario Agency for Health Protection, Promotion, Provincial Infectious Diseases Advisory Committee. Best practices for infection prevention and control programs in all health care settings. *Public health Ontario*; 2012. 87 p.
 17. Beattie M. A guide to infection control in the hospital. *Aust Infect Control*. 2001. 102 p;6(3). doi: 10.1071/HI01102.
 18. Al Knawvy B, Khoja T, Balkhy H, Pittet D. *GCC Infection control manual*; 2013. p. 1-324.
 19. Souza Dias MB, Cavassin LGT, Stempliuk V, Xavier LS, Lobo RD, Sampaio JLM, *et al*. Multi-institutional outbreak of *Burkholderia cepacia* complex associated with contaminated mannitol solution prepared in compounding pharmacy. *Am J Infect Control*. 2013 Nov;41(11):1038-42. doi: 10.1016/j.ajic.2013.01.033, PMID 23663863.
 20. Staes C, Jacobs J, Mayer J, Allen J. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12. *Am J Health Syst Pharm*. 2013 Aug 1;70(15):1301-12. doi: 10.2146/ajhp130049, PMID 23867487.
 21. Held MR, Begier EM, Beardsley DS, Browne FA, Martinello RA, Baltimore RS, *et al*. Life-threatening sepsis caused by *Burkholderia cepacia* from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. *Pediatrics*. 2006 Jul;118(1):e212-5. doi: 10.1542/peds.2005-2617, PMID 16785290.
 22. Mattner F, Gastmeier P. Bacterial contamination of multiple-dose vials: A prevalence study. *Am J Infect Control*. 2004;32(1):12-6. doi: 10.1016/j.ajic.2003.06.004, PMID 14755229.
 23. Stucki C, Sautter AM, Favet J, Bonnabry P. Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulations on end-product quality. *Am J Health Syst Pharm*. 2009 Nov 15;66(22):2032-6. doi: 10.2146/ajhp070681, PMID 19890087.
 24. Centers for Disease Control and Prevention (CDC). CDC grand rounds: preventing unsafe injection practices in the US health-care system. *MMWR Morb Mortal Wkly Rep*. 2013;62(21):423-5. PMID 23718950.
 25. Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. *MMWR Morb Mortal Wkly Rep*. 2012;61(41):839-42. PMID 23076093.
 26. Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, *et al*. Tennessee Fungal Meningitis Investigation Team. Fungal infections associated with contaminated methylprednisolone in Tennessee. *N Engl J Med*. 2012 Dec 6;367(23):2194-203. doi: 10.1056/NEJMoa1212972, PMID 23131029.
 27. Yablon BR, Dantes R, Tsai V, Lim R, Moulton-Meissner H, Arduino M, *et al*. Outbreak of *Pantoea agglomerans* Bloodstream Infections at an Oncology Clinic-Illinois, 2012-2013. *Infect Control Hosp Epidemiol*. 2017 Mar 1;38(3):314-9. doi: 10.1017/ice.2016.265, PMID 27919308.
 28. Selenic D, Dodson DR, Jensen B, Arduino MJ, Panlilio A, Archibald LK. Enterobacter cloacae bloodstream infections in pediatric patients traced to a hospital pharmacy. *Am J Health Syst Pharm*. 2003;60(14):1440-6. doi: 10.1093/ajhp/60.14.1440. PMID 12892028.
 29. Shehab N, Brown MN, Kallen AJ, Perz JF. US Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned. *J Patient Saf*. 2018;14(3):164-73. doi: 10.1097/PTS.000000000000188. PMID 26001553.
 30. Gershman MD, Kennedy DJ, Noble-Wang J, Kim C, Gullion J, Kacica M, *et al*. *Pseudomonas fluorescens* Investigation Team. Multistate outbreak of *Pseudomonas fluorescens* bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy. *Clin Infect Dis*. 2008 Dec;47(11):1372-9. doi: 10.1086/592968, PMID 18937575.
 31. Kastango ES, American Society of Health-System Pharmacists (ASHP). Blueprint for implementing USP chapter 797 for compounding sterile preparations. *Am J Health Syst Pharm*. 2005;62(12):1271-88. doi: 10.1093/ajhp/62.12.1271, PMID 15947127.
 32. United States Pharmacopeia, General Chapter USP <800> Hazardous Drugs-Handling in Healthcare Settings. The United States pharmacopeial convention. 2017. p. 1-20.
 33. Ontario: Provincial Infectious Diseases Advisory Committee. Public health Ontario. Best practices for cleaning, disinfection, and sterilization of medical equipment/devices in all health care settings. 110 p.